Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.68 |
| ▸ | MAPT | P10636 | 4/20 | 0.68 |
| ▸ | LMNA | P02545 | 4/20 | 0.68 |
| ▸ | THRB | P10828 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | SLC6A5 | Q9Y345 | 7/20 | 0.54 |
| ▸ | SLC6A9 | P48067 | 7/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | DPP4 | P27487 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29536266 | 1.00 | ALDH1A1 (0.68) | ALDH1A1MAPTLMNATHRBPOLB | |
| SCHEMBL6495866 | 0.96 | ALDH1A1 (0.63) | ALDH1A1MAPTLMNATHRBPOLB | |
| SCHEMBL31639893 | 0.96 | ALDH1A1 (0.63) | ALDH1A1MAPTLMNATHRBPOLB | |
| SCHEMBL10189346 | 0.92 | MAPT (0.60) | ALDH1A1MAPTLMNATHRBPOLB | |
| SCHEMBL27178641 | 0.91 | MAPT (0.68) | ALDH1A1MAPTLMNATHRBPOLB | |
| SCHEMBL10035920 | 0.90 | ALDH1A1 (0.56) | ALDH1A1MAPTLMNATHRBPOLB | |
| SCHEMBL29554755 | 0.90 | ALDH1A1 (0.56) | ALDH1A1MAPTLMNATHRBPOLB | |
| SCHEMBL27178872 | 0.90 | ALDH1A1 (0.56) | ALDH1A1MAPTLMNATHRBPOLB | |
| SCHEMBL31334721 | 0.90 | ALDH1A1 (0.56) | ALDH1A1MAPTLMNATHRBPOLB | |
| SCHEMBL31333796 | 0.90 | ALDH1A1 (0.55) | ALDH1A1MAPTLMNATHRBPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 170 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4398904-A1 | SELECTED COMPOUNDS FOR TARGETED DEGRADATION OF BRD9 | C4 Therapeutics, Inc. (US) | 2024-07-17 | — | — | EP | claimed |
| CN-117720516-A | Advantageous crystalline forms of selective BRD9 degrading agents | C4医药公司 | 2024-03-19 | — | — | CN | claimed |
| WO-2023039208-A1 | SELECTED COMPOUNDS FOR TARGETED DEGRADATION OF BRD9 | C4 THERAPEUTICS, INC. (US) | 2023-03-16 | — | — | WO | claimed |
| EP-4709720-A1 | INHIBITORS AND DEGRADERS OF PIP4K PROTEIN | Larkspur Biosciences, Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| US-20260007681-A1 | INDOLE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | UNIV MICHIGAN (US) | 2026-01-08 | — | — | US | disclosed |
| US-20260000676-A1 | CHROMAN DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | UNIV MICHIGAN REGENTS (US) | 2026-01-01 | — | — | US | disclosed |
| US-20250367193-A1 | BIFUNCTIONAL COMPOUNDS CONTAINING SUBSTITUTED PYRIMIDINE DERIVATIVES FOR DEGRADING CYCLIN-DEPENDENT KINASE 2 VIA UBIQUITIN PROTEASOME PATHWAY | NIKANG THERAPEUTICS INC (DE) | 2025-12-04 | — | — | US | disclosed |
| US-12486253-B2 | Therapeutics for the degradation of mutant BRAF | C4 THERAPEUTICS, INC. (US) | 2025-12-02 | — | — | US | disclosed |
| EP-4652161-A1 | 2,4-DIANILINOPYRIMIDINE-BASED AURORA-A KINASE SELECTIVE DEGRADATION INDUCING COMPOUNDS | Uppthera, Inc. (KR) | 2025-11-26 | — | — | EP | disclosed |
| EP-4640686-A1 | DEGRADER FOR DEGRADING BRD PROTEIN AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | Innocure Therapeutics, Inc. (KR) | 2025-10-29 | — | — | EP | disclosed |
| US-20250325677-A1 | STAT6 DEGRADERS | GILEAD SCIENCES INC (US) | 2025-10-23 | — | — | US | disclosed |
| US-20040220194-A1 | 2-Alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists | SCHERING CORPORATION | 2004-11-04 | — | — | US | disclosed |
| US-20040220194-A1 | 2-Alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists | SCHERING CORPORATION | 2004-11-04 | — | — | US | disclosed |
| WO-2004018439-A1 | NOVEL ANTIBACTERIAL AGENTS | ORCHID CHEMICALS & PHARMACEUTICALS LTD (IN) | 2004-03-04 | — | — | WO | disclosed |
| EP-0640077-B1 | OXAZOLIDINONES CONTAINING A SUBSTITUTED DIAZINE MOIETY AND THEIR USE AS ANTIMICROBIALS | UPJOHN CO (US) | 2002-06-26 | — | — | EP | disclosed |
| CN-1044236-C | Oxazolidinone antimicrobials containing substituted diazine moieties | PHARMACIA UPJOHN CO (US) | 1999-07-21 | — | — | CN | disclosed |
| US-5700799-A | MICROBIOCIDES FOR TREATING HUMAN OR ANIMAL DISEASES | PHARMACIA & UPJOHN COMPANY (US) | 1997-12-23 | — | — | US | disclosed |
| US-5547950-A | FOR TREATING DRUG RESISTANT STAPHYLOCOCCUS AND STREPTOCOCCUS INFECTIONS | THE UPJOHN COMPANY (US) | 1996-08-20 | — | — | US | disclosed |
| EP-0640077-A1 | OXAZOLIDINONES CONTAINING A SUBSTITUTED DIAZINE MOIETY AND THEIR USE AS ANTIMICROBIALS | PHARMACIA & UPJOHN COMPANY (US) | 1995-03-01 | — | — | EP | disclosed |
| WO-1993023384-A1 | OXAZOLIDINONES CONTAINING A SUBSTITUTED DIAZINE MOIETY AND THEIR USE AS ANTIMICROBIALS | THE UPJOHN COMPANY (US) | 1993-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12486253-B2 | Therapeutics for the degradation of mutant BRAF | BRAF, NRAS, KRAS | ALDH1A1 1471/4885MAPT 1093/4885LMNA 3122/4885 |
| US-20250325677-A1 | STAT6 DEGRADERS | STAT6, STAT5B, STAT1 | ALDH1A1 959/4885MAPT 1017/4885LMNA 2978/4885 |
| US-20250367193-A1 | BIFUNCTIONAL COMPOUNDS CONTAINING SUBSTITUTED PYRIMIDINE DERIVATIVES FOR DEGRADING CYCLIN-DEPENDENT KINASE 2 VIA UBIQUITIN PROTEASOME PATHWAY | CDK2, SKP2, CCNK | ALDH1A1 3087/4885MAPT 2877/4885LMNA 2421/4885 |
| US-20040220194-A1 | 2-Alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists | ADORA2A, ADORA3, ADORA1 | ALDH1A1 591/4885MAPT 2814/4885LMNA 4065/4885 |
| US-20260000676-A1 | CHROMAN DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | ESRRA, ESR2, ESRRB | ALDH1A1 633/4885MAPT 4644/4885LMNA 2015/4885 |
| US-20260007681-A1 | INDOLE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | ESRRA, ESR2, AR | ALDH1A1 512/4885MAPT 4310/4885LMNA 3179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.